1 Supplementary information

2 A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell

3 lymphoma growth via inducing cell cycle arrest and apoptosis

- 4 Cuiting Peng^{1,3 #}, Changzhen Sun^{2, #}, Ningyu Wang⁴, Yuanmin He¹, Jixiang Xu¹, Lanyang Gao⁵,
- 5 Yongqiong Deng¹, Jianqiao Zhong¹, Xia Xiong¹, Li Liu^{1,*}
- 6 ¹ Department of dermatology, The affiliated hospital of Southwest Medical University, Luzhou,
- 7 China.
- 8 ² Drug Research Center of Integrated Traditional Chinese and Western Medicine, Affiliated
- 9 Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.
- 10 ³ Department of Obstetrics& Gynecology, West China Second University Hospital, Sichuan
- 11 University, Chengdu, China.
- ⁴ School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China.
- ⁵ Department of Science and Technology, The affiliated hospital of Southwest Medical University,
- 14 Luzhou, China.
- 15 *These authors contributed equally to this study.
- * Address correspondence to Li Liu: liuli@swmu.edu.cn

- 17 The structure of the YLT-LL-11 was characterized by nuclear magnetic resonance
- 18 (NMR) and mass spectrometry (MS).

19

- ¹H NMR (400 MHz, DMSO- d_6) δ 10.49 (s, 1H), 9.80 (s, 1H), 7.71 (dd, J = 7.8, 1.7 Hz, 1H), 7.59 –
- 21 7.52 (m, 1H), 7.16 (d, J = 8.3 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 6.67 (d, J = 4.4 Hz, 3H), 4.41 (dd, J = 4.4 Hz, 3H), 4.50 (dd, J = 4.4 Hz, 3H), 4.51 (dd, J = 4.4 Hz, 4H), 4
- 22 = 7.8, 4.5 Hz, 1H), 3.89 (s, 3H), 1.74 (m, J = 7.4, 4.5 Hz, 1H), 1.65 (m, J = 14.5, 7.4 Hz, 1H), 0.91 (t,
- 23 J = 7.4 Hz, 3H).
- 24 13 C NMR (101 MHz, DMSO- d_6) δ 166.27, 156.79, 143.01, 135.48, 133.48, 130.75, 126.66, 124.10,
- 25 120.51, 115.95, 114.57, 113.22, 109.16, 77.55, 56.54, 23.67, 9.51.
- 26 Mass spectrometry (ESI, *m/z*): 361.0869 [M-H]⁻.

27 Supplementary Table 1 Primers used in real-time PCR

Application	sequences (5' to 3')
c-Myc-forward	GCCACGTCTCCACACATCAG
c-Myc-reverse	TCTTGGCAGCAGGATAGTCCTT
BRD4- forward	ACCTCCAACCCTAACAAGCC
BRD4-reverse	TTTCCATAGTGTCTTGAGCACC
GAPDH- forward	GCGATGCTGGCGCTGAGTACGTCG
GAPDH-reverse	GGGCATCAGCAGAGGGGGCAGAGA